Go Pro

ThinkEquity's Rating of Regentis Biomaterials on 3/2/2026

On March 2, 2026, ThinkEquity updated its outlook on Regentis Biomaterials (NYSEAMERICAN:RGNT) with the action "Upgrade", setting a "Strong-Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from ThinkEquity

DateCompanyAction
8/17/2026
Unusual Machines, Inc. stock logo
UMAC
Unusual Machines
Reiterated Rating
8/3/2026
Micron Technology, Inc. stock logo
MU
Micron Technology
Reiterated Rating
7/20/2026
AtlasClear Holdings, Inc. stock logo
ATCH
AtlasClear
Initiated Coverage
6/29/2026
Super League Enterprise, Inc. stock logo
SLE
Super League Enterprise
Initiated Coverage
6/15/2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
Initiated Coverage
6/15/2026
Greenland Energy Co stock logo
GLND
Greenland Energy
Initiated Coverage
More Ratings From ThinkEquity